Related Experiment Video

Updated: Feb 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes

Adam Ioannou1, Irene Tsappa2, Sofia Metaxa3

  • 1Cardiology Department, Royal Free NHS Foundation Trust, London, UK.

Patient Related Outcome Measures
|November 16, 2017
PubMed

Insights

Apixaban, a novel oral anticoagulant, is a popular factor Xa inhibitor for preventing stroke in atrial fibrillation patients. This review examines its pivotal trials, real-world data, effectiveness, safety, and economic viability.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation is a common arrhythmia with a high risk of thromboembolic stroke.
  • Vitamin K antagonists were traditional stroke prophylaxis, but novel oral anticoagulants (NOACs) are now widely used.
  • Apixaban is a leading NOAC, specifically a factor Xa inhibitor.

Purpose of the Study:

  • To review the pivotal trials that led to apixaban's development.
  • To critically evaluate emerging real-world data on apixaban.
  • To discuss the effectiveness, safety, economic viability, and future prospects of apixaban in non-valvular atrial fibrillation (NVAF).

Main Methods:

  • Review of pivotal clinical trials for apixaban.
  • Analysis of real-world evidence and observational studies.
  • Assessment of safety, efficacy, and economic data.

Main Results:

  • Apixaban has demonstrated significant efficacy and safety in pivotal trials for stroke prevention in NVAF.
  • Real-world data generally support the findings from clinical trials.
  • Apixaban offers a favorable profile regarding bleeding risk and overall patient outcomes.

Conclusions:

  • Apixaban is a highly effective and safe option for stroke prevention in patients with non-valvular atrial fibrillation.
  • Its established efficacy, safety, and economic viability support its widespread use.
  • Ongoing evaluation of real-world data will further refine its role in patient management.

Keywords:
apixabanatrial fibrillationbleedingstrokewarfarin

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
488
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K